Navigation Links
Neurocrine Biosciences Reports Fourth Quarter And Year End 2012 Results
Date:2/8/2013

.m. Eastern Time (5:00 a.m. Pacific Time). Participants can access the live conference call by dialing 866-952-1906 (US) or 785-424-1825 (International) using the conference ID: NBIX. The call can also be accessed via the webcast through the Company's website at http://www.neurocrine.com.

If you are unable to attend the webcast and would like further information on this announcement please contact the Investor Relations Department at Neurocrine Biosciences at (858) 617-7600. A replay of the conference call will be available approximately one hour after the conclusion of the call by dialing 800-388-6197 (US) or 402-220-1115 (International) using the conference ID: NBIX. The call will be archived for two weeks.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine-related diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world, including endometriosis, tardive dyskinesia, uterine fibroids, stress-related disorders, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders.  Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.

In addition to historical facts, this press release may contain forward-looking statements that involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with Neurocrine's business and finances in general, as well as risks and uncertainties associated with the Company's R & D pipeline and Company overall. Specifically, the risks and uncertainties the Company faces with respect to the Company's R & D pipeline include risk that the ongoing Phase III endometriosis clinica
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Neurocrine Biosciences To Present At The 24th Annual Piper Jaffray Healthcare Conference
2. Neurocrine Biosciences Reports Third Quarter 2012 Results
3. Neurocrine Biosciences Reports Second Quarter 2012 Results
4. Neurocrine Biosciences to Present at The 24th Annual Roth Conference
5. Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
6. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
7. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
8. IntelliCell BioSciences Announces the Addition of Harry Fisch, MD as Director of Urology
9. Avelas Biosciences Closes $7.65 Million Series A, Advances Real-Time Tumor Visualization Technology Toward Development
10. Pressure BioSciences, Inc. Appoints Conrad F. Mir as Chief Financial Officer
11. IntelliCell BioSciences Announces Research Agreement with the New Jersey Center for Biomaterials at Rutgers-The State University of New Jersey
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2014)... 28, 2014 The American Association ... University’s School of Nursing with a very prestigious ... program. The 2014 Innovations in Professional Nursing Education ... schools and supports them as they re-envision traditional ... at AACN’s annual meeting in Washington, D.C. to ...
(Date:11/27/2014)... Research and Markets  has announced the ... 2014" report to their offering. ... Acid Industry Report 2014 is a professional and in-depth ... acid industry. The report provides a basic ... industry chain structure. The palmitic acid market analysis is ...
(Date:11/27/2014)... -- Calcivis, a medical devices company ... today announces that it has completed a first ... System. The Calcivis Caries Activity Imaging ... combination designed to transform the assessment and management ... unique, proprietary bioluminescence approach combined with a specialised ...
(Date:11/26/2014)... 26, 2014 The report on the ... segments the concerned market for revenue forecasts and market ... CAGR of 51.9% from 2013 to 2018. At the ... value of $1,415.6 million by 2018. , Browse through ... TOC for information about the market segmentation and in-depth ...
Breaking Biology Technology:American Association of Colleges of Nursing honors Fairfield University’s School of Nursing for Re-envisioning Nursing Education 2Global Palmitic Acid Industry Report 2014 2Calcivis Completes Clinical Study of Novel Caries Activity Imaging System 2Calcivis Completes Clinical Study of Novel Caries Activity Imaging System 3Global Smart Sensor Market in Building Automation is expected to reach a value of $1,415.6 million by 2018 - Report by MicroMarket Monitor 2Global Smart Sensor Market in Building Automation is expected to reach a value of $1,415.6 million by 2018 - Report by MicroMarket Monitor 3Global Smart Sensor Market in Building Automation is expected to reach a value of $1,415.6 million by 2018 - Report by MicroMarket Monitor 4
... VIENNA, Austria, November 28 f-star, an antibody,engineering company ... Modular Antibody Technology, today announced that it,has raised EUR ... of its Series,A financing round, originally co-led by Aescap ... raised in the Series A round,increases to EUR 9.0 ...
... 1-41 has significant ... and anti-amnesic benefits, GENEVA, Nov. 28 /PRNewswire-FirstCall/ - ... announce promising developments with,ANAVEX 1-41, the company,s lead drug ... 1-41 prevented oxidative stress,which damages and destroys cells and ...
... November 28 The results of a,study on ... desensitisation product, which is due to receive German ... VO52.06, which was carried out on 280,patients in ... the main evaluation criterion by,demonstrating a statistically significant ...
Cached Biology Technology:Antibody Engineering Company f-star Raises EUR 3.0 Million in a Second Closing of its Series A Financing Round From Novo A/S 2Antibody Engineering Company f-star Raises EUR 3.0 Million in a Second Closing of its Series A Financing Round From Novo A/S 3Anavex advances drug candidate for treatment of Alzheimer's disease 2Anavex advances drug candidate for treatment of Alzheimer's disease 3Anavex advances drug candidate for treatment of Alzheimer's disease 4Anavex advances drug candidate for treatment of Alzheimer's disease 5STALLERGENES: ORALAIR Grasses: Positive Results of VO52.06 Paediatric Study 2
(Date:11/4/2014)... PA) – Temple University School of Medicine announced ... winner, an initiative funded by the Bill & ... Professor of Obstetrics, Gynecology and Reproductive Sciences; and ... Temple University School of Medicine will pursue an ... "Maternal Blood Biomarkers to Assess Fetal Neurodevelopment.", Grand ...
(Date:11/4/2014)... 4, 2014   ...   Fuel3D , a developer of 3D ... round totaling $6.4 million (£4 million). This funding builds on ... this year and paves the way for the commercial launch ... The funding round was led by Chimera Partners and will ...
(Date:11/3/2014)... Research and Markets has announced the addition of a ... to their offering. This report describes ... started to play an important role in the practice of ... bone marrow transplants. Role of cells in drug discovery is ... of medical practice. Stem cells are discussed in ...
Breaking Biology News(10 mins):Temple University School of Medicine receives Grand Challenges Explorations grant 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3
... (March 18, 2009) As any parent knows, children ... University of Washington and the Monell Center indicates that ... and is related to children,s high growth rate. ... sense because when growth is rapid, caloric demands increase. ...
... Mrs. Bruce Reid recorded seeing both a male and ... 1938, Oscar McKinley Bryans observed a ruby-throated hummingbird in ... apple trees were blooming. These are just two of ... on notecards in government files. The cards record more ...
... 2009 Dr. Daniel Von Hoff, Physician-In-Chief of the ... recognizing his achievements in cancer research. Dr. Von ... Clinical Research Services at Scottsdale Healthcare, will be recognized ... special report this month in Arizona Business Magazine. ...
Cached Biology News:Liking sweets makes sense for kids 2It's for the birds 2It's for the birds 3TGen's Dr. Von Hoff wins award for cancer research 2
Human PDGF R beta MAb (Clone # PR7212)...
Zebrafish Ephrin-B2 Biotinylated Affinity Purified PAb...
Collected from 8-12 week old New Zealand or Californian rabbits. Aseptically collected and processed to minimize hemolytic activity. Pricing: $60/unit for 1 - 10 units...
One-step, microplate or cuvet, colorimetric, detection range 0.3 g/dL to 5 g/dL. Procedure: 5 min....
Biology Products: